(-)-Epinephrine (+)-bitartrate: Non-Selective Adrenergic Receptor Agonist for Cardiovascular and Sympathetic Research

Executive Summary: (-)-Epinephrine (+)-bitartrate (L-Epinephrine Bitartrate, Adrenaline Bitartrate) is a non-selective adrenergic receptor agonist engaging α₁/α₂ and β₁/β₂/β₃ subtypes with nanomolar EC₅₀ values (5–10 nM) in standardized cell assays (Liu et al. 2019). It is widely used in vitro and in vivo for cardiovascular, neurobiology, and sympathetic nervous system research. The product is highly soluble in water (≥22.9 mg/mL) and DMSO (≥16.66 mg/mL), but insoluble in ethanol, with recommended storage at -20°C to maintain stability (APExBIO). Clinical and preclinical protocols employ precise dosing regimens, typically 0.3–0.5 mg intramuscularly in adults. Overdose risks include hypertension and arrhythmias, and use is contraindicated in pheochromocytoma or hyperthyroidism. Benchmark studies confirm robust and reproducible adrenergic receptor activation (see DOI).

Biological Rationale

(-)-Epinephrine (+)-bitartrate is a synthetic salt form of the endogenous catecholamine epinephrine. It activates both α- and β-adrenergic receptors, which are key mediators in the sympathetic nervous system. These receptors regulate cardiovascular tone, bronchodilation, and metabolic pathways. Non-selective adrenergic agonists such as (-)-Epinephrine (+)-bitartrate are crucial for dissecting the integrated responses of these pathways in animal models and cell-based assays (Pro-Adrenomedullin 2024). This compound enables precise modulation of signaling, heart rate, vasoconstriction, and airway smooth muscle relaxation, making it indispensable for cardiovascular disease research, sympathetic signaling studies, and translational pharmacology.

Mechanism of Action of (-)-Epinephrine (+)-bitartrate

As a non-selective adrenergic receptor agonist, (-)-Epinephrine (+)-bitartrate binds and activates multiple receptor subtypes:

• α₁-adrenergic receptor: Induces vasoconstriction, elevating blood pressure (EC₅₀ ≈ 5 nM in cell-based assays).
• α₂-adrenergic receptor: Modulates neurotransmitter release and vascular tone.
• β₁-adrenergic receptor: Increases cardiac contractility and heart rate (EC₅₀ ≈ 10 nM).
• β₂-adrenergic receptor: Promotes bronchodilation, facilitating airflow (EC₅₀ ≈ 8 nM).
• β₃-adrenergic receptor: Influences lipolysis and energy metabolism.

Upon receptor engagement, downstream signaling involves G-protein coupled receptor activation, cAMP production, and protein kinase A pathways. The result is rapid physiological modulation suited to emergency responses and experimental manipulation of sympathetic tone. APExBIO provides (-)-Epinephrine (+)-bitartrate (B1358) as a high-purity, research-grade reagent for these mechanisms (see product details).

Evidence & Benchmarks

• Binding constant (K_b) measurements for β₂-adrenergic receptor and epinephrine analogs confirm nanomolar affinity, enabling quantitative receptor pharmacology studies (Liu et al. 2019).
• Solubility benchmarks: ≥22.9 mg/mL in water, ≥16.66 mg/mL in DMSO, insoluble in ethanol; suitable for aqueous and DMSO-based assays (APExBIO).
• In vitro assay concentrations typically range from 1 nM to 10 μM for cell signaling and receptor activation (OctocryleneMolecule 2024).
• In vivo dosing established at 0.15–0.3 mg intramuscularly and 2–20 mg intranasally in canine models (APExBIO).
• Clinical emergency protocols for anaphylaxis employ 0.3–0.5 mg IM for adults (0.01 mg/kg pediatric), reflecting translational alignment (EPGLabs 2024).

Applications, Limits & Misconceptions

(-)-Epinephrine (+)-bitartrate is established for:

• Cell signaling assays dissecting adrenergic receptor activation and downstream pathways (Alpha-1-Antitrypsin-Fragment 2024).
• In vivo cardiovascular and bronchial reactivity studies in animal models.
• Acute interventions: anaphylactic shock, bronchospasm, and as a local anesthesia adjuvant.
• Pharmacokinetic and receptor binding studies using advanced techniques (e.g., open-tubular capillary electrochromatography; Liu et al. 2019).

Common Pitfalls or Misconceptions

• Not effective in patients with pheochromocytoma or hyperthyroidism due to risk of hypertensive crisis.
• Overdose can cause severe arrhythmias and life-threatening hypertension.
• Loss of potency if solutions are not freshly prepared or are exposed to light/oxygen for extended periods.
• Ineffective as a selective agonist—does not distinguish between adrenergic receptor subtypes.
• Insoluble in ethanol—improper solvent use can lead to failed assays.

This article extends prior coverage on Epinephrine Bitartrate's validation by providing updated quantitative benchmarks and addressing workflow parameters. It also clarifies mechanistic distinctions not fully elaborated in previous reviews and updates translational dosing insights from recent studies.

Workflow Integration & Parameters

• Preparation: Dissolve at ≥22.9 mg/mL in water or ≥16.66 mg/mL in DMSO. Avoid ethanol.
• Storage: Store powder at -20°C; prepare fresh solutions before use to prevent degradation (APExBIO).
• Assay Range: Use 1 nM–10 μM for in vitro; refer to validated in vivo dosages for animal studies.
• Controls: Include vehicle and receptor antagonist controls for specificity.
• Documentation: Reference batch and preparation conditions for reproducibility.

Conclusion & Outlook

(-)-Epinephrine (+)-bitartrate remains a gold-standard adrenergic receptor agonist for cardiovascular, neurobiology, and sympathetic nervous system research. Its robust affinity profile, validated dosing, and clear solubility/storage parameters support its continued use in both basic and translational workflows. Future studies may further refine receptor subtype selectivity and application in precision medicine. For detailed product specifications, see the APExBIO (-)-Epinephrine (+)-bitartrate page.